Indian stock markets experienced a turbulent Friday, September 26, 2025, with both the Sensex and Nifty indices facing significant downturns. The Sensex fell over 200 points, while the Nifty dipped below the 24,850 mark. This decline marks the sixth consecutive session of losses for the Indian benchmark indices.

Market Performance

The S&P BSE Sensex opened at 80,956.01, down by 203.67 points, and the NSE Nifty 50 started at 24,818.55, a decrease of 72.3 points. The Sensex closed the previous session at 81,159.68, a loss of 555.95 points or 0.7%, while the Nifty 50 ended at 24,890.85, shedding 166.05 points or 0.7%.

Several factors contributed to this negative sentiment, including persistent foreign capital outflows, concerns about U.S. visa restrictions, and anxieties over potential trade tariffs. U.S. President Donald Trump's announcement of a 100% tariff on branded drugs and a 25% tariff on heavy-duty trucks entering the U.S. further exacerbated the situation, particularly impacting pharmaceutical stocks.

Top Losers and Gainers

Pharmaceutical stocks were among the hardest hit, with Sun Pharma leading the losses with a slip of up to 4%. Other notable losers included Bajaj Finance and Asian Paints. Conversely, L&T, BEL, and Tata Steel were among the gainers, providing some cushion against the overall decline.

Broader market indices also reflected the downturn, with the Nifty MidCap 100 index dropping by 0.21% and the Nifty SmallCap 100 index falling by 0.37%. Sectorally, the Nifty Pharma index experienced a significant plunge due to the imposed tariffs on patented drug imports.

Sun Pharma's Performance

Sun Pharmaceutical Industries Ltd., a major player in the pharmaceutical sector, faced a challenging day. The stock's last traded price was ₹1,627.40, a marginal increase of 0.02% compared to the previous day. However, the stock has fallen by 0.47% compared to the previous week and 1.07% over the last month. Over the past year, the stock has decreased by 13.16%. The stock opened at Rs 1590.6, marking a decline of 2.3% from the previous close.

Analysts' opinions on Sun Pharma's future price are mixed, with a maximum estimate of ₹2,450.00 and a minimum estimate of ₹1,525.00. Several firms have maintained their ratings on the stock, with Nuvama recommending a 'Hold' with a target price of ₹1,830, and Morgan Stanley reiterating an 'Overweight' rating with a target price of ₹1,948.

Titan's Performance

Titan Company Ltd also experienced a downward trend, with its share price decreasing by 1.16% to ₹3,378.50. The stock has fallen by 4.29% compared to the previous week and 7.76% over the last month. Over the past year, Titan has shown a decrease of 11.09%.

Analysts have provided varying estimates for Titan's future price, with a maximum estimate of ₹4,615.00 and a minimum estimate of ₹3,200.00.

Global Influences

U.S. stocks also declined for a third consecutive session on Thursday, influenced by an unexpected decrease in jobless claims and a significant upward revision to GDP growth. The Nasdaq Composite index fell by 0.5%, the S&P 500 ended 0.5% down, and the Dow Jones Industrial Average decreased by approximately 0.38%.

Market Outlook

The Indian stock market is currently experiencing a period of volatility, influenced by both domestic and global factors. Investors are closely monitoring foreign capital flows, U.S. visa policies, and international trade relations. Technical analysts suggest that the Nifty 50 faces resistance between 25,000 and 25,050, with support in the 24,700-24,750 range.